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Abstract
Background: Metabolic syndrome (METS) is an increasingly prevalent but poorly understood clinical condition
characterized by insulin resistance, glucose intolerance, dyslipidemia, hypertension, and obesity. Increased oxidative
stress catalyzed by accumulation of iron in excess of physiologic requirements has been implicated in the
pathogenesis of METS, but the relationships between cause and effect remain uncertain. We tested the hypothesis
that phlebotomy-induced reduction of body iron stores would alter the clinical presentation of METS, using a
randomized trial.
Methods: In a randomized, controlled, single-blind clinical trial, 64 patients with METS were randomly assigned to
iron reduction by phlebotomy (n = 33) or to a control group (n = 31), which was offered phlebotomy at the end
of the study (waiting-list design). The iron-reduction patients had 300 ml of blood removed at entry and between
250 and 500 ml removed after 4 weeks, depending on ferritin levels at study entry. Primary outcomes were change
in systolic blood pressure (SBP) and insulin sensitivity as measured by Homeostatic Model Assessment (HOMA)
index after 6 weeks. Secondary outcomes included HbA1c, plasma glucose, blood lipids, and heart rate (HR).
Results: SBP decreased from 148.5 ± 12.3 mmHg to 130.5 ± 11.8 mmHg in the phlebotomy group, and from 144.7 ±
14.4 mmHg to 143.8 ± 11.9 mmHg in the control group (difference -16.6 mmHg; 95% CI -20.7 to -12.5; P < 0.001). No
significant effect on HOMA index was seen. With regard to secondary outcomes, blood glucose, HbA1c, low-density
lipoprotein/high-density lipoprotein ratio, and HR were significantly decreased by phlebotomy. Changes in BP and
HOMA index correlated with ferritin reduction.
Conclusions: In patients with METS, phlebotomy, with consecutive reduction of body iron stores, lowered BP and
resulted in improvements in markers of cardiovascular risk and glycemic control. Blood donation may have
beneficial effects for blood donors with METS.
Trial registration: ClinicalTrials.gov: NCT01328210
Please see related article: http://www.biomedcentral.com/1741-7015/10/53
Background
Metabolic syndrome (METS), a condition characterized
by insulin resistance, glucose intolerance, dyslipidemia,
hypertension, and obesity [1], affects approximately a
quarter of the population in the USA [2] and is becoming
increasingly prevalent in Europe [3]. The pathogenesis of
METS is incompletely understood, but recent studies
have suggested that oxidative stress catalyzed by accumu-
lation of iron in excess of physiologic requirements may
be contributory [4].
Previous findings have indicated an association
between accumulated iron and the components of
METS, including hypertension and diabetes mellitus.
Serum ferritin levels correlate with hypertensive retino-
pathy [5], and clinical hypertension is characterized by a
higher prevalence of increased iron stores [6]. In two
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type and increased transferrin saturation were associated
with increased risk of requirement for antihypertensive
medication [7]. A positive association between iron stores
and insulin resistance or diabetes mellitus has been found
in numerous epidemiologic studies [8-12]. Furthermore,
both, ferritin and transferrin were shown to be signifi-
cantly associated with the presence of the METS and its
components [13,14]. Notably, increased ferritin levels
may be a determinant for METS in postmenopausal
w o m e nb u tn o ti np r e m e n o p a u s a lw o m e n[ 1 5 ] .I tw a s
further suggested that iron overload may be crucial for
non-alcoholic fatty liver disease (NAFLD) in METS [16],
and raised ferritin levels were found to be independent
predictors of vascular damage in NAFLD and METS [17].
Similarly, there is recent evidence that reduction of
body iron stores may improve the symptoms of METS.
Iron-chelating agents and blood donation can prevent
the development of diabetes in iron overload [18,19].
Depleting iron stores in type 2 diabetes by phlebotomy
may favorably increase insulin sensitivity in carriers of
the HFE mutation [20] and in patients with diabetes [21].
In earlier studies, repeated phlebotomy resulted in
decreases in serum glucose and blood lipids [22]. In
patients with non-alcoholic steatohepatitis, blood-letting
also led to decreased insulin concentrations [23]. More-
over, it was reported that a low-iron diet positively influ-
ences cardiovascular risk in type 2 diabetes [24]. Finally,
in an uncontrolled observational study on 15 patients
with essential hypertension resistant to a triple drug regi-
men, repeated phlebotomy resulted in a pronounced
reduction in blood pressure (BP) [25]. Iron-mediated oxi-
dative stress may modulate vascular tone [26,27], and
hepcidin, a key iron regulatory peptide, correlates with
vascular damage in METS [28]
Western populations have a high prevalence of raised
iron stores [29], thus if iron reduction can beneficially
affect METS, this would have considerable public-health
significance, as well as being beneficial for the health of
the donor in certain conditions.
As the effects of iron reductive therapy in METS have
not been previously addressed systematically, we designed
a randomized clinical trial to measure the effects of phle-
botomy on BP, insulin sensitivity, and cardiovascular risk
factors in patients with METS.
Methods
This randomized controlled trial was performed in a single
centre (Kliniken-Essen-Mitte, an academic teaching hospi-
tal of the University Duisburg-Essen). Patients were
enrolled between June and December 2008, and interven-
tion and follow-up were completed in March 2009. The
study was approved by the Ethics Committee of the Medi-
cal Faculty of the University Hospital Essen and is regis-
tered at ClinicalTrials.gov, NCT01328210. Informed con-
sent was obtained from all patients.
Participants
Patients aged 25 to 70 years old with presumed METS
were recruited through press advertisements and general
(family) practices. Patients were required to have three or
more of the following criteria: 1) abdominal adiposity
(waist circumference ≥1020 mm (men) or ≥880 mm
(women)); 2) low levels of high-density lipoprotein choles-
terol (HDL-C): ≤40 mg/dL (men) or ≤50 mg/dL
(women)); 3) hypertriglyceridemia (≥150 mg/dL); 4) raised
BP (≥130/85 mmHg); and 5) impaired glucose homeostasis
(fasting plasma glucose ≥110 mg/dL). Enrollment criteria
were reviewed in a screening telephone call, and con-
firmed by examination at the first study visit. Exclusion
criteria included: 1) clinically significant other organic dis-
ease including malignancy; 2) history of hemochromatosis
or presence of the Cys282Tyr mutation; 3) history of drug
or alcohol misuse 4); history of disturbances in iron bal-
ance (for example,, iron overload or deficiency); and 5)
anemia (hemoglobin < 12 g/dL).
Of the 113 patients that expressed interest in partici-
pating, 72 were invited to the clinic for more detailed
investigation. Based on the results, 64 patients were
included in the study. The population was generally
middle-aged, predominantly female, and overweight
population. Pre-existing diabetes was present in 38%,
and nearly all had hypertension (Table 1).
Randomization
The 64 patients were randomly allocated to either the
iron-reduction group (n = 33) or the control group (n =
31). Baseline characteristics were balanced between
groups. The patients were randomized by means of a
non-stratified block randomization method with ran-
domly varying block lengths based on the ‘ranuni’
pseudo-random number generator of the SAS/Base
® sta-
tistical software (SAS Inc., Cary NC, USA). For each
patient, the biostatistician prepared sealed, sequentially
numbered, opaque envelopes containing the treatment
assignments. Each time a patient fulfilled all enrolment
criteria, the study physician opened the lowest num-
bered envelope to reveal that patient’s assignment. Allo-
cation of treatment was not blinded. Data were
collected by trained blinded study personnel.
All patients received standard medical care as deter-
mined by their individual requirements. All participants
were instructed to continue their usual treatment with
medication, and were specifically advised to maintain
their usual diet and physical activity, and to abstain
from any other new treatments for METS.
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Iron-reduction group
The phlebotomy intervention consisted of removal of two
volumes of blood: one at entry to the study and one at day
28. Phlebotomy was performed while patients lay in the
supine position. The skin was disinfected, then blood was
collected via the cubital arm vein. At the first phlebotomy
session, 300 ml of blood were removed. At the second cali-
brated blood removal, the volume removed varied in
accordance with the entry level of ferritin concentration:
(250 ml for patients with ferritin < 90 ng/ml, 350 ml with
90 to 200 ng/ml, and 500 ml with > 200 ng/mL).
Control group
Patients allocated to the control group received no spe-
cific treatment, but were offered phlebotomy at the end
of the 6-week study period to ensure study compliance
(waiting list design).
Outcome measurements
Physical measurements were taken in a quiet room while
participants were in the fasting state. They were asked to
refrain from smoking or caffeine for at least 60 minutes
before their appointment time. BP measurements were
standardized for cuff size, position, and time of day. After
10 minutes of quiet rest, two seated measurements of BP
on the non-dominant arm and the heart rate (HR) were
recorded with an automatic sphygmomanometer (Dyna-
map, Criticon, Norderstedt, Germany). At each assess-
ment, two readings, taken with an interval of 5 minutes,
were averaged to obtain the BP.
For laboratory investigations, a blood sample was drawn
at baseline and at 6 weeks. An additional blood sample
was collected in the bloodletting group at 4 weeks. Insulin
sensitivity was estimated by the homeostasis model assess-
ment (HOMA) index, and calculated as fasting plasma
glucose (mmol/l) × serum insulin (μU/ml) ÷ 25.
Blood count and assays for blood lipids, HbA1c, ferritin
and iron were performed using standard methods. Serum
concentrations of insulin and high-sensitivity C-reactive
proten (hs-CRP) were measured by immunonephelometry
(BNiI-nephelometer, Siemens, Fernwald, Germany), and
adiponectin concentrations were measured by radioimmu-
noassay (DRG Instruments, Marburg, Germany) at the
Central Laboratory of University Hospital Essen.
Physical activity and nutritional habits were assessed
by standardized self-reports and diaries. Adverse events
( A E s )w e r em o n i t o r e db yd i a r ya n da tt h ef i n a ls t u d y
visit by interview.
There were two main outcome parameters in this
study: change in SBP and change in HOMA index, from
week 0 (pre-treatment) to week 6.
Sample size determination and statistical analysis
We expected an effect size of 0.7 for the HOMA index
and calculated that a sample size of 64 patients would be
needed to give a power of b = 80% by means of a two-
sided t-test with a = 5%. This approximates the effect of
iron reduction on insulin sensitivity as measured by an
intravenous insulin tolerance test in patients with type 2
diabetes patients given in a previous trial [21], in which a
standardized effect of d = 0.78 was verified. Given the
assumption that the intravenous insulin tolerance test
might be more sensitive than the HOMA index, we con-
sidered that a hypothetical estimated effect size of 0.5
w o u l dy i e l das a m p l es i z eo fn=1 3 0 .N od a t af r o mc o n -
trolled trials were available for the estimate of the effect of
phlebotomy on BP, but we expected an effect size of
greater than 0.5 for this primary outcome. Finally, sample
size calculation was based on an expected effect size of
d = 0.7 with 64 patients.
All statistical analyses were performed using the SAS
statistical analysis package (version 9.2; SAS Inc., Cary,
NC, USA). They were carried out on an intention-to-treat
basis including all randomized patients irrespective of
their adherence to the study protocol. Missing data were
multiply imputed using Markov chain Monte Carlo meth-
ods [30]. For each outcome parameter, this gave a total of
20 complete data sets,. These were each separately ana-
l y z e db yu n i v a r i a t ea n a l y s i so fc o v a r i a n c e( A N C O V A ) ,
which included group and baseline values as covariates.
Finally, the results were adequately combined to produce
Table 1 Clinical baseline characteristics of the study population
Treatment group (n = 33) Control group (n = 31) P value
Age, years 60 ± 6 57 ± 11 0.52
Gender, F/M 13/20 14/17 0.88
Weight, kg 95.0 ± 18.9 92.6 ± 16.1 0.60
Body mass index, kg/m
2 32.8 ± 5.5 32.5 ± 5.6 0.88
Waist circumference, cm 109.0 ± 11.3 108.9 ± 13.5 0.98
Type 2 diabetes, n (%) 10 (30) 14(45) 0.22
Drug intake, n (%) 31 (94) 24 (77) 0.06
History of hypertension, n (%) 32 (97) 31 (100) 0.33
History of smoking, n (%) 2 (6) 7 (23) 0.06
Data a mean ± SD unless indicated otherwise.
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and P values. To avoid multiple statistical errors, the P
values for both primary outcome parameters were
adjusted in accordance with the Bonferroni-Holm proce-
dure [31].
Results
Two patients in each group withdrew during the course
of the study course because they were unable to return
for follow-up. These patients reported during a tele-
phone interview that they were satisfied with the study
procedures and had not experienced any AEs (Figure 1).
Hence, 29 patients in the control group and 31 in the
treatment group completed the study.
In the iron reduction group, all patients received two
phlebotomies in accordance with the study protocol.
Mean hemoglobin decreased from 14.3 ± 1.2 at baseline
to 13.3 ± 1.1 mg/dl after 6 weeks, and similarly, mean
serum ferritin concentration decreased from 188.3 ±
212.4 to 104.6 ± 132.5 mg/dl. Medication was not modi-
fied during the study. Lifestyle habits including the
amount of exercise and type and quantity of food intake,
^ƚƵĚǇ&ůŽǁŝĂŐƌĂŵ
Assessed for eligibility (n=121 ) 
Excluded  (n=57   ) 
♦Not meeting inclusion criteria (n=50) 
♦Declined to participate (n=5) 
♦Other reasons (n=2 ) 
Intention-to-treat population (n=33) 
Analysed  (n=31) 

Lost to follow-up (n=2) 
(unwillingness to return for study visit)  
Allocated to intervention group (n=33) 
♦Received allocated intervention (n=33)
Lost to follow-up (n=2) 
(unwillingness to return for study visit)   
Allocated to control group (n=31) 
Intention-to-treat population (n=31) 







Figure 1 Study flow chart. Numbers of patients who were enrolled and included in the analysis.
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ingly, mean body mass index and waist circumference




The iron-reduction had a lowering of BP (Table 2) com-
pared with the control group. After 6 weeks, the reduction
in SBP was 18.3 ± 10.5 mmHg in the phlebotomy group
and 0.2 ± 7.7 mmHg in the control group, resulting in a
group difference of -16.5 mmHg (95% CI -20.6 to -12.3;
P < 0.001). Hence, at study end, 25 patients (81%) of the
control group were classified as hypertensive (BP ≥140/90
mmHg) compared with only 13 patients (39%) in the phle-
botomy group.
HOMA index
The HOMA index decreased from 4.8 ± 7.2 to 3.6 ± 2.7
in the iron-reduction group and from 4.5 ± 3.8 to 4.1 ±
3.6 in the control groups, resulting in a group difference
of -0.7; 95% CI 2.1 to 0.6), but this was not significant
(P = 0.29).
Secondary outcome measures
Diastolic BP was significantly reduced (P < 0.001) by iron
reduction. Furthermore, patients in this group had signifi-
cant reductions in HR compared with the control group
(P < 0.001) (Table 2).
Although the HOMA index did not indicate a signifi-
cant increase in insulin sensitivity, plasma glucose and
HbA1C were found to be significantly decreased in the
iron-reduction group compared with the control group
(P < 0.001 for both). No consistent changes in blood
lipids could be verified in this study, but non-significant
changes in low-density lipoprotein cholesterol (LDL-C)
and HDL-C favoring the iron-reduction group resulted in
a significant improvement in the LDL/HDL ratio (P <
0.01). Blood concentrations of adiponectin, hs-CRP and
insulin were not changed by phlebotomy (Table 3).
We further analyzed the role of ferritin depletion and
decreases in hemoglobin/hematocrit in the beneficial
effect of blood-letting. Changes in SBP and serum ferri-
tin concentration were significantly correlated with each
other (Spearman’s r =0 . 4 1 ;P = 0.02). Furthermore, the
non-significant improvement of HOMA index correlated
with the decrease in serum ferritin concentration (r =
0.39; P = 0.03). No associations were found between
changes in hematocrit, hemoglobin, red blood cell
count, and outcomes.
Safety
All patients tolerated the iron reduction by phlebotomy
well, and no serious AEs occurred. In total, eight of the
patients in the phlebotomy group reported mild AEs:
four reported initial headaches that lasted for a few
hours; three reported mild symptoms of dizziness,
Table 2 Primary and secondary outcomes with group differences for change after treatment










Diff. 95% CI P value
Primary outcomes
SPB, mmHg 148.5 ± 12.3 130.5 ± 11.9 144.7 ± 14.4 143.8 ± 11.9 -16.5 -20.6 to 12.3 < 0.001
HOMA index 4.8 ± 7.2 3.6 ± 2.7 4.5 ± 3.8 4.1 ± 3.6 -0.7 -2.1 to 0.6 0.28
Secondary outcomes
Glucose, mg/dl 110.7 ± 29.4 98.5 ± 24.0 109.1 ± 34.4 107.3 ± 33.6 -13.3 -18.8 to -8.1 < 0.001
HbA1c, % 5.56 ± 0.61 5.36 ± 0.58 5.84 ± 1.24 5.72 ± 1.24 -0.19 -0.29 to -0.08 < 0.001
Insulin, μU/ml 15.4 ± 17.7 14.2 ± 8.9 16.7 ± 12.7 15.2 ± 11.6 -1.2 -5.4 to 3.0 0.580
Adiponectin, μg/ml 9.15 ± 3.40 9.83 ± 5.00 8.75 ± 4.00 9.40 ± 4.40 0.24 -0.90 to 1.39 0.68
hs-CRP, mg/dl 0.32 ± 0.44 0.33 ± 0.39 0.30 ± 0.37 0.31 ± 0.38 0.01 -0.05 to 0.07 0.80
DBP, mmHg 93.2 ± 6.8 83.7 ± 5.7 90.8 ± 6.6 90.0 ± 8.6 -8.2 -10.7 to -5.7 < 0.001
Heart rate, beats/min 72.1 ± 8.2 70.0 ± 5.8 74.2 ± 9.5 76.2 ± 8.4 -5.7 -8.1 to -3.2) < 0.001
Ferritin, ng/ml 188.3 ± 212.4 104.6 ± 132.5 173.2 ± 132.9 149.4 ± 124.9* -74.2 101.6 to -46.8 < 0.001
Iron, ng/ml 100.6 ± 34.2 75.8 ± 28.5 100.8 ± 26.2 102.8 ± 36.9* -27.1 -41.1 to -13.2 < 0.001
Triglycerides, mg/dl 154.0 ± 66.7 158.0 ± 64.7 204.6 ± 120.0 178. ± 70.7* -2.9 -31.4 to 25.6 0.84
Cholesterol, mg/dl 208.4 ± 36.5 212.2 ± 38.6 211.0 ± 37.7 206.4 ± 36.4* 3.1 -6.7 to 12.8 0.54
HDL-C, mg/dl 55.9 ± 15.0 58.9 ± 17.9 54.2 ± 16.5 55.0 ± 16.1* 3.0 -0.3 to 6.3 0.07
LDL-C, mg/dl 131.2 ± 35.8 123.5 ± 35.9 130.7 ± 32.8 125.1 ± 29.1* -4.9 -11.8 to 2.0 0.16
LDL/HDL ratio 2.48 ± 0.88 2.21 ± 0.80 2.56 ± 0.82 2.43 ± 0.82 -0.23 -0.38 to -0.08 < 0.01
Abbreviations: DBP, diastolic blood pressure; HDL-C, HDL cholesterol; hs-CRP, high-sensitivity C-reactive protein; HOMA, homeostasis model assessment; LDL-C,
LDL cholesterol; SBP, Systolic Blood Pressure: adjusted.
aMean values ± SD at baseline and after 6 weeks and mean difference (95% confidence interval).
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patient had symptoms of fatigue for a few days. All
patients of the phlebotomy group rated the procedure as
tolerable, and the majority as very well tolerable (85%).
All but one patient stated that they would be happy to
undergo repeated phlebotomies.
Discussion
This randomized clinical trial examined the effects of
phlebotomy and controlled reduction of body iron in
patients with METS. Reduction in iron stores resulted
in substantial reduction in BP and improvement in gly-
cemic control, LDL/HDL ratio, and resting HR at 6
weeks. No significant effect on insulin sensitivity was
seen. Changes in BP and of insulin sensitivity correlated
with decreases in serum ferritin concentration.
To our knowledge, there have been no randomized trials
to date evaluating the effects of phlebotomy and iron
reduction in METS or hypertension. However, an anti-
hypertensive effect of repeated phlebotomy was described
in an early uncontrolled study on 15 patients with hyper-
tension resistant to triple antihypertensive medication
[25]. In that study, phlebotomy lowered mean BP from
140.1 ± 12.2 mmHg to 123.8 ± 14.9 mmHg after 14 days.
In another uncontrolled study, 12 patients with renal
transplant and erythrocytosis received three phlebotomies
of 500 ml over 6 weeks, which induced BP reductions
from 153/95 mmHg to 139/85 mmHg [32].
Arterial hypertension, which affects about one-third of
the adult population in the USA and Europe, causes
enormous morbidity and mortality. Antihypertensive
drug therapy is efficient and reduces morbidity and
mortality, but is costly and causes undesirable AEs. In
our study, we found a mean reduction in SBP of > 15
mmHg, indicating a clinically relevant effect. It has been
estimated that that a 22% reduction in coronary events
and a 41% reduction in stroke can be expected for a
reduction in SBP of 10 mm Hg [33]. Furthermore, the
observed reduction in resting HR of about 5 beats/min
may translate to further cardiovascular risk reduction.
The effect of iron reduction on glucose metabolism
was not consistent in our study. Whereas blood glucose
and HbA1c were significantly reduced after iron-reduc-
tion therapy, there were no changes in insulin sensitivity
or adiponectin secretion. In muscle, iron interferes with
glucose uptake [34], and increased iron stores predict
the development of diabetes in epidemiological studies
[8-11]. A previous study found beneficial effects of phle-
botomy in patients with type 2 diabetes with increased
ferritin concentration [21]. In that study, patients 500
ml of blood removed three times at 2-weekly intervals,
which resulted in a mean ferritin reduction from 500 to
230 ng/ml and significant reductions in HbA1c and
HOMA index after 4 months. In a small safety study on
blood donation, phlebotomy resulted ina significant
decrease in serum glucose and blood lipids in patients
with diabetes [22]. Iron reduction by phlebotomy also
enhanced insulin sensitivity in patients with iron-
induced insulin resistance and in carriers of the hemo-
chromatosis gene [20]. Notably, in these studies, the
amount of removed blood was larger than in our study
and the study period was longer. Furthermore, we did
not specify any predefined target ferritin level, and only
a moderate ferritin reduction was achieved. Thus, it may
be that the shorter duration of our study and the mod-
erate reduction in body iron stores were not sufficient
to improve insulin sensitivity. Moreover, the putative
anti-diabetic effect of blood removal is likely to be more
pronounced in patients with higher iron stores. The
magnitude of effect might be smaller in an unselected
population of patients with metabolic syndrome. In
addition, measurement of insulin sensitivity by the
HOMA method we used differs from intravenous meth-
ods. Given the assumption that the intravenous insulin
tolerance test is more sensitive than the HOMA index,
our trial might have been underpowered. Therefore, our
results should be interpreted with caution regarding
insulin sensitivity, and the clinical effect of iron reduc-
tion on insulin sensitivity in METS will need to be veri-
fied in larger trials.
We also found a modest effect of iron-reduction ther-
apy on blood lipids, with an improved LDL/HDL ratio.
In an earlier study, repeated phlebotomies decreased
concentrations of triglycerides and total cholesterol [22].
In light of our findings, further evaluation of the effects
of phlebotomy on blood lipids and metabolism seems
warranted. Results from a controlled trial in patients
with peripheral arterial disease found improved out-
comes after iron reduction in younger and middle-aged
subjects [35]. Our findings support a putative beneficial
effect of iron reduction by phlebotomy on factors that
can promote atherosclerosis.
The mechanisms responsible for the beneficial effects
of venesection and blood letting in METS also need to
be addressed. Based on our results, reductions in BP
and HOMA index correlate significantly with ferritin
reduction. Iron-catalyzed oxidative stress may have a
negative effect on METS and BP through several
mechanisms. In human monocytes of patients with
hyperferritinemia associated with METS, manipulation
of iron status induced cytokine release, and the degree
of induction was correlated with carotid atherosclerosis
[28]. Endothelium-dependent vasodilation is affected by
oxidative stress, and thus iron-mediated oxidative stress
may modulate vascular tone [26]. Generation of excess
free oxygen radicals and loss of redox homeostasis have
been related to insulin signaling, vascular tone, and
associated cardiovascular functional abnormalities, with
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in redox homeostasis [4] However, some cardiovascular
effects may also be related to the hemodynamic and
hematologic consequences of phlebotomies. The reduc-
tion in blood volume caused by phlebotomy may lead to
decreased extracellular fluid volume, peripheral resis-
tance, and reductions in blood viscosity [36]. It was esti-
mated that a 10% increase in hematocrit produces a
20% increase in blood viscosity, and that vasodilation or
an increase of BP are required to compensate physiolo-
gically for the increased viscosity [37]. Thus, particularly
in vessels with low vasodilatory capacity, phlebotomy
might induce an additional antihypertensive effect by
causing a reduction in viscosity.
The results of the present study should be interpreted
in light of certain limitations inherent to the study
design. Firstly, the study intervention was not blinded,
and therefore we cannot exclude the possibility that
non-specific effects contributed to the effectiveness of
the intervention. We attempted to reduce the effects of
disappointment in the control group by offering iron
reduction therapy at the end of the study period, and
we found that overall satisfaction with study participa-
tion was not different between groups. Secondly, we
could not control for the lifestyle habits of our patients
during the study. Patient self-reports and interviews and
the unchanged BMI and waist circumference measure-
ments did not indicate that relevant lifestyle changes
had occurred in our study patients; however, modifica-
tions in diet and physical exercise over a short 6-week
period could result in biochemical effects and reductions
in BP without producing significant variations in weight
a n dB M I .T h i r d l y ,t h ed e f i n i t i o no fM E T Si sn o tv e r y
specific, and our sample of patients was small; thus, our
results may not be applicable to patients with METS in
general. Finally, the study follow-up was limited to 6
weeks in this proof-of-concept study and, therefore, the
results of the present trial should be regarded as preli-
minary. Further trials with longer observation periods
should evaluate the long-term effects and potential
rebound effects of phlebotomy therapy.
Conclusion
In patients with METS, phlebotomy with moderate
reduction of body iron stores lowered BP and resulted
in improvements of markers of cardiovascular risk and
glycemic control. We propose that adequately con-
trolled phlebotomy could be considered as a cost-effec-
tive additional treatment option in METS. Furthermore,
a beneficial health-related effect for blood donation
might be a motivating factor to encourage more people
to donate blood, providing public healthcare benefits as
well.
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